Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Celltrion (068270) Posts Record Consolidated Revenue of KRW 4.16T and Operating Profit of KRW 1.17T for FY2025, Surge of 137.49% YoY

Posted on February 5, 2026July 14, 2026 By K-STOCK Editor No Comments on [Disclosure] Celltrion (068270) Posts Record Consolidated Revenue of KRW 4.16T and Operating Profit of KRW 1.17T for FY2025, Surge of 137.49% YoY

Fact Source: Financial Supervisory Service DART / 2026-02-05

Disclosure Type: Consolidated Financial Results (Tentative)

💡 3-Second Summary

Celltrion has delivered a stellar performance for fiscal year 2025, posting consolidated revenue of approximately KRW 4.16 trillion and operating profit of KRW 1.17 trillion, marked by a massive 137.49% year-on-year surge in annual operating income.

📊 1. [Summary of Key Disclosure Content and Major Figures]

  • Reporting Period: Q4 2025 (당기) and FY2025 Cumulative Tentative Performance
  • Information Provider: Celltrion IR Office

[Q4 2025 Performance (Unit: KRW Million)]

  • Revenue: KRW 1,330,157 million (Approx. KRW 1.33T)
    • Increased by 29.27% compared to the previous quarter (Q3 2025: KRW 1,028,969 million).
    • Increased by 25.06% compared to the same period last year (Q4 2024: KRW 1,063,649 million).
  • Operating Profit: KRW 475,172 million (Approx. KRW 475.2B)
    • Increased by 57.65% compared to the previous quarter (Q3 2025: KRW 301,412 million).
    • Increased by 141.94% compared to the same period last year (Q4 2024: KRW 196,404 million).
  • Net Income: KRW 527,928 million (Approx. KRW 527.9B)
    • Increased by 59.05% compared to the previous quarter (Q3 2025: KRW 331,923 million).
    • Increased by 124.11% compared to the same period last year (Q4 2024: KRW 235,569 million).

[FY2025 Cumulative Annual Performance (Unit: KRW Million)]

  • Cumulative Revenue: KRW 4,162,495 million (Approx. KRW 4.16T)
    • Increased by 17.01% compared to the prior year (FY2024: KRW 3,557,304 million).
  • Cumulative Operating Profit: KRW 1,168,471 million (Approx. KRW 1.17T)
    • Increased by 137.49% compared to the prior year (FY2024: KRW 492,016 million).
  • Cumulative Net Income: KRW 1,031,484 million (Approx. KRW 1.03T)
    • Increased by 146.25% compared to the prior year (FY2024: KRW 418,883 million).

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This tentative earnings release marks a pivotal operational development, demonstrating that Celltrion’s core business model and margin structure have firmly normalized. Achieving annual revenue of KRW 4.16T and growing its operating income by over 137% year-on-year to KRW 1.17T serves as a robust indicator of the company’s long-term fundamental expansion potential.

The quarterly performance in Q4 2025 is particularly encouraging, with both revenue (KRW 1.33T) and operating profit (KRW 475.2B) achieving outstanding double-digit sequential and yearly growth. The fact that operating profit grew at a significantly faster rate than top-line revenue indicates structurally improving operational leverage, which could introduce a potential impact of accelerating future cash flow projections.

However, as highlighted in the disclosure, these metrics are based on internal tentative calculations and are subject to change prior to the completion of the external audit. Furthermore, since the disclosure does not specify the concrete reasons for the earnings fluctuations, investors is likely to wait for the audited final statements and subsequent IR presentations to dissect specific product margins and post-merger synergy dynamics.

📝 Editor’s Comment (by K-STOCK Editor)

Celltrion has officially entered the KRW 1 trillion operating profit club with an earnings-surprise-level tentative report. Recording a Q4 operating margin exceeding 35% along with sequential top-line growth shows a high level of quarterly profitability. However, as the disclosure does not specify the concrete reasons for these earnings fluctuations, we must await the audited final statements to confirm the exact drivers. While the audited finalization remains ahead, the sheer strength of this fundamental showing provides a reassuring baseline for the stock. Market participants could view these robust cash flows as a positive catalyst that supports management’s broader shareholder value-up initiatives in the upcoming annual meetings.

📢 Disclaimer and Source Information

Source: This content was newly structured and written based on official data submitted to the Financial Supervisory Service’s electronic disclosure system (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] KRX Warning: Wonik IPS (240810) Faces Potential 1-Day Trading Suspension Risk on Feb 5 Amid Parabolic Overheating
Next Post: [Disclosure] Celltrion (068270) Reports FY2025 Consolidated Revenue of KRW 4.16T and Operating Profit of KRW 1.17T, Surge of 137.49% YoY on Improved Cost Structure

Related Posts

[Disclosure] Celltrion 068270 Reports Q3 Provisional Revenue of KRW 1.03T and Operating Profit of KRW 301.0B… Surging 44.95% YoY Disclosures
[Disclosure] Samsung Biologics(207940) Submits FY2023 Financial Statements with ‘Unmodified’ Auditor’s Opinion Disclosures
[Disclosure] Alteogen(196170) to Hold IR at ‘J.P. Morgan 2026 Healthcare Conference’ in San Francisco, U.S. Disclosures
[Disclosure] Alteogen (196170) Cancels Merger Between Subsidiaries Altos Biologics and Alteogen Healthcare Due to An Error in Calculating the Merger Ratio Disclosures
[Disclosure] SK hynix Inc. (000660) Details $45.46B KRW Nasdaq ADR Issuance—Funding Advanced Fabs and EUV Scanners Semiconductors
[Disclosure] Alteogen (196170) Hits Jackpot: Signs KRW 867.5B Exclusive License Deal with Global Big Pharma Biogen for ALT-B4 Bio & Healthcare

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Celltrion (068270) Submits Application to Modify Phase 3 Clinical Trial Plan for ‘CT-P44’ (Darzalex Biosimilar) in EuropeJuly 14, 2026
  • [Disclosure] Hanmi Semiconductor (042700) Reports Q2 2026 Operating Profit of KRW 130.3B… A Explosive 1,441.4% QoQ SurgeJuly 14, 2026
  • [Disclosure] SK Square (402340) Discloses Subsidiary SK Hynix’s Successful ADR Listing on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] SK Hynix (000660) Completes Listing of ADRs (American Depositary Receipts) on the U.S. NASDAQ MarketJuly 13, 2026
  • [Disclosure] Samsung Electronics (005930) to Dispose of KRW 322.8B Worth of Treasury Shares for Executive BonusesJuly 13, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme